Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Antibiotic Treatment Clear all
Completed Not applicable Interventional Results available

The INSPIRE-ASP UTI Trial

NCT03697096
View directory record Official record
Conditions
Urinary Tract Infection (UTI)
Interventions
Routine Care, INSPIRE CPOE Smart Prompt
Other
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
18 Years and older
Enrollment
55,412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
59
States / cities
Riverside, California • San Jose, California • Thousand Oaks, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Results available

Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

NCT00798577
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Vigamox Ophthalmic Solution, BSS placebo
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Year and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2010 · Synced Jun 7, 2026, 6:18 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Or v IV Antibiotics for Infection

NCT04723940
View directory record Official record
Conditions
Joint Infection
Interventions
Bactrim, Cefadroxil, Doxycycline Hcl, Clindamycin
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Jun 7, 2026, 6:18 AM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Jun 7, 2026, 6:18 AM EDT
Not yet recruiting Phase 3 Interventional

Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans

NCT07104318
View directory record Official record
Conditions
Helicobacter Pylori
Interventions
Bismuth quadruple therapy with optimized PPI, Bismuth quadruple therapy with standard PPI, Clarithromycin triple therapy with optimized PPI, Clarithromycin triple therapy with standard PPI, Standard bismuth quadruple therapy
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 7, 2026, 6:18 AM EDT
Not yet recruiting Phase 2 Interventional

B-PaLMZ for TB Meningitis

NCT07227779
View directory record Official record
Conditions
Tuberculous Meningitis
Interventions
BPaLMZ Regimen
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Results available

Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)

NCT01450800
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Nitrofurantoin, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years and older · Female only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Jun 7, 2026, 6:18 AM EDT
Available No phase listed Expanded access

Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

NCT04513821
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
Mino-Lok Therapy (MLT)
Drug
Lead sponsor
Leonard-Meron Biosciences, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
27
States / cities
Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Jun 7, 2026, 6:18 AM EDT
Terminated Phase 3 Interventional

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00324324
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jun 7, 2026, 6:18 AM EDT
Not yet recruiting Early Phase 1 Interventional

Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection

NCT07494773
View directory record Official record
Conditions
Burns, Wound Infection
Interventions
Methylene Blue, Blue Light Illumination
Drug · Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Autologous Fecal Therapy

NCT02046525
View directory record Official record
Conditions
Infectious Disease of Digestive Tract
Interventions
Autologous fecal microbiota therapy, Placebo
Biological · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Jun 7, 2026, 6:18 AM EDT
Terminated Phase 4 Interventional Results available

Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia

NCT02478710
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated
Interventions
Aerosolized Tobramycin or Vancomycin, Aerosolized Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Jun 7, 2026, 6:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Perspectives on Prophylactic Antibiotic Use in Dermatologic Surgery

NCT04150523
View directory record Official record
Conditions
Medication Adherence
Interventions
Survey
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
8
States / cities
Davis, California • Indianapolis, Indiana • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Antibiotics Versus Surgery for Treating Acute Appendicitis

NCT02447224
View directory record Official record
Conditions
Acute Uncomplicated Appendicitis
Interventions
1 gm IV ertapenem at enrollment, 1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days, Appendectomy
Drug · Procedure
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
5 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

NCT01695343
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
KB001-A, Placebo Comparator
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
58
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Jun 7, 2026, 6:18 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children

NCT06285812
View directory record Official record
Conditions
Otitis Media Acute
Interventions
OtoSight Middle Ear Scope
Device
Lead sponsor
PhotoniCare, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 7, 2026, 6:18 AM EDT
Completed No phase listed Observational

Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit

NCT05171257
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
IV antibiotic treatment from prior, differing IV antibiotic treatment
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

NCT00351273
View directory record Official record
Conditions
Arthritis, Reactive, Reiter Disease
Interventions
Doxycycline and Rifampin, Azithromycin and Rifampin, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Tampa, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Jun 7, 2026, 6:18 AM EDT
Terminated Phase 1 Interventional Results available

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

NCT02527681
View directory record Official record
Conditions
Bacterial Infections
Interventions
Ceftobiprole medocaril
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
Up to 3 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Loma Linda, California • Los Angeles, California • South Bend, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 3 Interventional

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

NCT00563433
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
ofloxacin, MSI-78
Drug
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics

NCT01019395
View directory record Official record
Conditions
Gram Positive Bacterial Infection
Interventions
Daptomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
3 Months to 24 Months
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jun 7, 2026, 6:18 AM EDT
Recruiting Phase 1 Interventional

A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension

NCT06481852
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

NCT01128530
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections
Interventions
JNJ-32729463, linezolid, JNJ-32729463 placebo, linezolid placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
27
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Jun 7, 2026, 6:18 AM EDT
Recruiting Phase 1 Interventional

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

NCT03546829
View directory record Official record
Conditions
Early Stage Non-Small Cell Lung Cancer
Interventions
Vancomycin, Precision hypofractionated radiation
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jun 7, 2026, 6:18 AM EDT